Document:

EX-10.1

 Exhibit 10.1 

Zosano Pharma Corporation 

ZP Opco, Inc. 
 34790
Ardentech Court 
 Fremont, CA 94555 

August 9, 2017 
 John Walker 

 

	 	Re:	Employment Agreement 

 Dear John: 

This letter will confirm the terms and conditions of your employment with ZP Opco, Inc., a Delaware corporation (the
“Company”) and a wholly owned subsidiary of Zosano Pharma Corporation, a Delaware corporation (the “Parent”). This letter supersedes and replaces that certain Consulting Agreement dated as of
May 8, 2017 by and among the Parent, the Company and you (the “Consulting Agreement”), which terminates according to its terms effective as of the Start Date (as defined below). 

1.    Position and Duties. Effective August 9, 2017 (the “Start Date”), you
will be the President and Chief Executive Officer of the Parent and the Company. Like other officers of the Parent, you will be an employee of the Company. You will report to the Board of Directors of the Parent (the
“Board”). You agree to perform the duties of your positions and such other duties as may reasonably be assigned to you from time to time by the Board. You also agree that, while employed by the Company, you will
devote 75% of your business time, and your best efforts, business judgment, skill and knowledge to the advancement of the business and interests of the Parent, the Company and their respective Affiliates (as defined in Section 6) and to the
discharge of your duties and responsibilities for them. 
 2.    Compensation and Benefits. During your
employment, as compensation for the services performed by you for the Company and its Affiliates, the Company will provide you the following pay and benefits: 

(a)    Base Salary. Effective on the Start Date, the Company will pay you a base salary at the rate of $360,000
per year, payable in accordance with the regular payroll practices of the Company and subject to increase from time to time by the Compensation Committee of the Board (the “Compensation Committee”) in its discretion. 

(b)    Bonus Compensation. During employment, you will be considered annually for a bonus. The amount of
any bonus awarded will be determined by the Board of Directors in its discretion, and will be based on your performance and the performance of the Company against goals established annually. 

 John Walker 

August 9, 2017 
  Page
 2
 
  

 (c)    Stock Options. 

(i)    The Compensation Committee shall grant you an incentive stock option to purchase 300,000 shares (the
“Option”) of common stock, $0.0001 par value per share, of Parent (“Common Stock”). 

(ii)    The Option shall (A) have an exercise price per share equal to the closing price per share of Common Stock
on the date of the grant, and (B) be subject to vesting requirements such that 25% of the Option shares shall vest on the first anniversary of the date of grant and an additional 1/48th of
the total Option shares shall vest thereafter on the monthly anniversary of such date. 
 (iii)    Notwithstanding any
other provision of the Option or any other stock option or equity incentive award that is granted to you by the Parent in the future (the “Outstanding Options”): (A) an amount equal to 25% of the Total Option Shares (as
defined below) shall vest upon termination of employment pursuant to the last sentence of Section 4(a) or the first sentence of Section 4(b); and (B) an amount equal to 100% of the Total Option Shares (as defined below) shall vest
upon a Constructive Termination Event (as defined in Section 5(b)). For purposes of this Section 2(c)(iii), the term “Total Option Shares” shall mean, as of any given day, the total amount of shares purchasable by,
or issuable to, you pursuant to any then Outstanding Option, without regard to the number of shares that are vested at such time pursuant to the terms of such Outstanding Options. 

(d)    Participation in Employee Benefit Plans. You shall be entitled to participate in any and all employee
benefit plans from time to time in effect for the full-time employees of the Company generally, but the Company shall not be required to establish any such program or plan. Such participation shall be subject to (i) the terms of the applicable
plan documents and (ii) generally applicable Company policies. The Company may alter, modify, add to or delete its employee benefit plans at any time as it, in its sole discretion, determines to be appropriate. 

(e)    Vacations. You will be entitled to three weeks of paid vacation per year, in addition to holidays observed
by the Company. Vacation may be taken at such times and intervals as you shall determine, subject to the reasonable business needs of the Company. 

(f)    Business Expenses. The Company will pay or reimburse you for all reasonable business expenses incurred or
paid by you in the performance of your duties and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such expenses set by the Company and to such reasonable substantiation and documentation as it may
specify from time to time. 
 3.    Confidential Information and Restricted Activities. 

(a)    Confidential Information. During the course of your employment with the Company, you will learn of
Confidential Information (as defined in Section 6), and you 

 John Walker 

August 9, 2017 
  Page
 3
 
  

 
may develop Confidential Information on behalf of the Company. You agree that you will not use or disclose to any Person (as defined in Section 6) any Confidential Information obtained by
you incident to your employment or any other association with the Company or any of its Affiliates, except as required by applicable law or for the proper performance of your regular duties and responsibilities for the Company. You understand that
this restriction shall continue to apply for three (3) years after your employment terminates, regardless of the reason for such termination. In addition, you agree to sign the Company’s standard form of invention assignment agreement as a
condition of your employment hereunder. 
 (b)    Protection of Documents. All documents, records and files, in
any media of whatever kind and description, relating to the business, present or otherwise, of the Parent, the Company or any of their respective Affiliates, and any copies, in whole or in part, thereof (the “Documents”),
whether or not prepared by you, shall be the sole and exclusive property of the Company. You agree to safeguard all Documents and to surrender to the Company, at the time your employment terminates or at such earlier time or times as the Board may
specify, all Documents then in your possession or control. 

(c)    Non-Solicitation. You acknowledge that in your employment with the
Company you will have access to Confidential Information which, if disclosed, would assist in competition against the Company and its Affiliates, and that you will also generate good will for the Company and its Affiliates in the course of your
employment. Therefore, you agree that the following restrictions on your activities during and after the termination of your employment are necessary to protect the good will, Confidential Information and other legitimate interests of the Company
and its Affiliates: While you are employed by the Company and during the 12 months immediately following termination of your employment for whatever reason, you shall not, directly or through any other Person, (A) seek to persuade any employee
of the Company or any of its Affiliates to discontinue employment or (B) solicit or encourage any customer, distributor, vendor, or other business partner of the Company or any of its Affiliates or any independent contractor providing services
to the Company or any of its Affiliates to terminate or diminish its relationship with them. For purposes of the foregoing, the terms “employee,” “customer,” “distributor,” and
“vendor” shall also include any person or party who held such status during the immediately preceding six (6) months. 

(d)    Enforcement of Restrictions. In signing this letter agreement, you give the Company assurance that you have
carefully read and considered all the terms and conditions of this letter agreement, including the restraints imposed on you under this Section 3. You agree without reservation that these restraints are necessary for the reasonable and proper
protection of the Company and its Affiliates, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area. You further agree that, were you to breach any of the covenants contained in
this Section 3, the damage to the Company and its Affiliates would be irreparable. You therefore agree that the Company, in addition to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against
any breach or threatened breach by you of any of those covenants, without having to post bond. You also agree that the period of restriction in Section 3(c) 

 John Walker 

August 9, 2017 
  Page
 4
 
  

 
shall be tolled and shall not run during any period you are in violation thereof. You and the Company further agree that, in the event that any provision of this Section 3 is determined by
any court of competent jurisdiction to be unenforceable by reason of its being extended over too great a time, too large a geographic area or too great a range of activities, that provision shall be deemed to be modified to permit its enforcement to
the maximum extent permitted by law. It is also agreed that each of the Company’s Affiliates shall have the right to enforce all of your obligations to that Affiliate under this letter agreement, including without limitation pursuant to this
Section 3. It is agreed and understood that the terms of this letter agreement are severable, and that no breach of any provision of this letter agreement or any other purported violation of law by the Company shall operate to excuse you from
the performance of your obligations under this Section 3. 
 4.     Termination of Employment. Your
employment under this letter agreement shall continue for no definite term until terminated pursuant to this Section 4. 

(a)    The Company may terminate your employment for Cause upon written notice to you setting forth in reasonable detail
the nature of the Cause (as defined below). The following, as determined by the Company in its reasonable judgment, shall constitute “Cause” for termination: (i) your persistent and willful refusal to follow reasonable
directives of the Board; (ii) gross negligence or willful misconduct in the performance of your duties and responsibilities to the Company or any of its Affiliates; (iii) your material breach of this letter agreement or any other agreement
between you and the Company or any of its Affiliates, which breach continues for more than 15 days after the Company gives you written notice which sets forth in reasonable detail the nature of such breach; or (iv) other conduct by you that is
or could reasonably anticipated to be materially harmful to the business, interests or reputation of the Company or any of its Affiliates. The Company also may terminate your employment other than for Cause upon written notice to you. 

(b)    You may terminate your employment for Good Reason (as defined below) upon written notice to the Company setting
forth in reasonable detail the nature of the Good Reason. The following shall constitute “Good Reason” for termination: (i) the Company’s failure to continue you in the position of President and Chief Executive
Officer of the Company with such duties typically associated with such position, or (ii) failure of the Company to provide you compensation and benefits in accordance with the terms of Section 2, above, for more than ten (10) business
days after notice from you specifying in reasonable detail the nature of such failure, except in connection with a decrease in salary affecting each senior management employee of the Company in a proportionate manner, (iii) relocation of your
principal place of employment to a location other than the greater San Francisco Bay area, California, or (iv) the failure of the Company’s successor to assume the Company’s obligations under this Agreement upon a Change in Control.
You may also terminate your employment other than for Good Reason upon 30 days’ written notice to the Company. 

(c)    In the event you become disabled during employment and, as a result, are unable to continue to perform
substantially all of your duties and responsibilities under this letter agreement, either with or without reasonable accommodation, the Company will continue 

 John Walker 

August 9, 2017 
  Page
 5
 
  

 
to pay you your base salary and to provide you benefits in accordance with Section 2(d) above, to the extent permitted by plan terms, for up to twelve (12) weeks of disability during
any period of three hundred and sixty-five (365) consecutive calendar days. If you are unable to return to work after twelve (12) weeks of disability, the Company may terminate your employment, upon notice to you. If any question shall
arise as to whether you are disabled to the extent that you are unable to perform substantially all of your duties and responsibilities for the Company and its Affiliates, you shall, at the Company’s request, submit to a medical examination by
a physician selected by the Company to whom you or your guardian, if any, has no reasonable objection to determine whether you are so disabled, and such determination shall for the purposes of this letter agreement be conclusive of the issue. If
such a question arises and you fail to submit to the requested medical examination, the Company’s determination of the issue shall be binding on you. 

5.    Severance Payments and Other Matters Related to Termination.  

(a)    Involuntary Termination. In the event of termination of your employment by the Company other than for Cause,
or in the event of your termination of employment for Good Reason in either case outside the Change in Control period stated in Section 5(b), the Company will (i) continue to pay you your base salary in effect at the time of such
termination (disregarding any decrease that forms the basis of a resignation for Good Reason pursuant to Section 4(b)(ii)) for a period of twelve (12) months from and after the date of termination, (ii) an amount equal to the annual
bonus awarded to you in respect of the prior calendar year, such bonus severance to be paid in equal installments during the twelve (12) month period following the date of termination, and (iii) continue to provide you with group medical,
dental and vision insurance for a period of twelve (12) months from and after the date of your termination. The Company will also pay you on the date of termination any base salary, bonus and other wages earned but not paid through the date of
termination, and pay for any vacation time accrued but not used to that date. In addition, as provided in Section 2(c), the vesting schedule for any stock options and other equity incentive awards outstanding on the date of termination will
automatically accelerate so that 25% of any then unvested option shares and other equity incentive awards shall immediately vest and become exercisable upon such termination. Except as set forth in clauses (ii) and (iii) of the first sentence
of this Section 5(a), benefits shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of your employment. 

(b)    Involuntary Termination within One Year after Change in Control. In the event of termination of your
employment by the Company (or its successor) other than for Cause, or in the event of your termination of employment for Good Reason, in either case during the one (1)-year period following a Change in Control (a “Constructive Termination
Event”), the Company (or its successor) will, in lieu of any severance under Section 5(a) above, pay you, upon receiving the signed Employee Release pursuant to Section 5(c),: (i) a lump sum severance payment equal to
twenty-four (24) months of your base salary in effect at the time of such termination (disregarding any decrease that forms the basis of a resignation for Good Reason pursuant to Section 4(b)(ii)), (ii) an amount equal to the annual bonus
awarded to you 

 John Walker 

August 9, 2017 
  Page
 6
 
  

 
in respect of the prior calendar year, and (iii) a lump sum cash amount equal to 229.56% multiplied by the total cost of the projected premiums for group medical, dental and vision insurance
for a period of twenty-four (24) months covering the period from and after the date of your termination. The Company (or its successor) will also pay you on the date of termination any base salary, bonus and other wages earned but not paid
through the date of termination, and pay for any vacation time accrued but not used to that date. In addition, as provided in Section 2(c), the vesting schedule for any stock options and other equity incentive awards outstanding on the date of
termination will automatically accelerate so that 100% of any then unvested option shares and other equity incentive awards shall immediately vest and become exercisable upon such termination. Except as set forth in clauses (ii) and (iii) of
the first sentence of this Section 5(b), benefits shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of your employment. 

(c)    Severance Conditional Upon Release. Any obligation of the Company to provide you severance payments under
Sections 5(a) and 5(b) above shall be conditioned upon your signing a general release of claims in the form provided by the Company and reasonably acceptable to you (the “Employee Release”) within twenty-one (21) days after the date on which you receive such Employee Release and upon your not revoking the Employee Release thereafter. Except as set forth in Section 5(b) regarding lump sum payments,
all base salary and bonus severance payments will be payable in accordance with the normal payroll practices of the Company and will begin at the Company’s (or its successor’s) next regular payroll period following the effective date of
the Employee Release, but shall be retroactive to the date of termination. For the avoidance of doubt, no cash compensation that may be earned by you pursuant to employment or a consulting arrangement with a Person other than the Company during the
period of time that the Company (or its successor) is making payments to you pursuant to this Section 5 shall be credited toward the Company’s severance obligations under this Section 5. Notwithstanding anything to the contrary
contained in this letter agreement, in the event that at the time of your separation from service you are a “specified employee,” as hereinafter defined, any and all amounts payable under this Section 5 in connection with such
separation from service that constitute deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), as determined by the Company in
its sole discretion, and that would (but for this sentence) be payable within six (6) months following such separation from service, shall instead be paid on the date that follows the date of such separation from service by six (6) months.
For purposes of the preceding sentence, “separation from service” shall be determined in a manner consistent with subsection (a)(2)(A)(i) of Section 409A and the term “specified employee” shall
mean an individual determined by the Company to be a specified employee as defined in subsection (a)(2)(B)(i) of Section 409A. 

(d)    Termination for Cause or Voluntary Termination. In the event of termination of your employment by the
Company for Cause or your termination other than for Good Reason, the Company will pay you any base salary and other wages earned but not paid through the date of termination and pay for any vacation time accrued but not used to that date. The
Company shall have no obligation to pay you any bonus compensation or severance 

 John Walker 

August 9, 2017 
  Page
 7
 
  

 
payments. Except for any right you may have under the federal law known as “COBRA” to continue participation in the Company’s group health and dental plans at your cost, benefits
shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of your employment. 

(e)    Survival of Certain Provisions. Provisions of this letter agreement shall survive any termination if so
provided in this letter agreement or if necessary or desirable to accomplish the purposes of other surviving provisions, including without limitation your obligations under Section 3 of this letter agreement. The obligation of the Company (or
its successor) to make severance payments to you under Section 5(a) or 5(b) above, and your right to retain such payments, are expressly conditioned upon your continued full performance of your obligations under Section 3 hereof. Upon
termination by either you or the Company, all rights, duties and obligations of you and the Company to each other shall cease, except as otherwise expressly provided in this letter agreement. 

6.    Definitions. For purposes of this letter agreement, the following definitions apply: 

“Affiliates” means all persons and entities directly or indirectly controlling, controlled by or under common control
with the Company, where control may be by management authority, equity interest or otherwise. 
 “Confidential
Information” means any and all information of the Company and its Affiliates that is not generally available to the public. Confidential Information also includes any information received by the Company or any of its Affiliates from any
Person with any understanding, express or implied, that it will not be disclosed. Confidential Information does not include information that enters the public domain, other than through your breach of your obligations under this letter agreement.

 “Change in Control” means (A) the sale, lease, exchange, transfer or other disposition of all or
substantially all of the assets of the Company or its Affiliates (other than Zosano, Inc.), or (B) any merger, consolidation, acquisition of the Company, or other business combination or stock sale (other than a sale of stock for capital
raising purposes) that results in the holders of the outstanding voting securities of the Company or Parent immediately prior to such transaction beneficially owning or controlling immediately after such transaction less than a majority of the
voting securities of the Company or Parent, respectively, or the surviving entity or the entity that controls such surviving entity. 

“Person” means an individual, a corporation, a limited liability company, an association, a partnership, an estate, a
trust or any other entity or organization, other than the Company or any of its Affiliates. 
 7.    Conflicting
Agreements. You hereby represent and warrant that your signing of this letter agreement and the performance of your obligations under it will not breach or be in conflict with any other agreement to which you are a party or are bound, and that
you are not 

 John Walker 

August 9, 2017 
  Page
 8
 
  

 
now subject to any covenants against competition or similar covenants or any court orders that could affect the performance of your obligations under this letter agreement. You agree that you
will not disclose to or use on behalf of the Company any proprietary information of a third party without that party’s consent. 

8.    Withholding. All payments made by the Company under this letter agreement shall be reduced by any tax or
other amounts required to be withheld by the Company under applicable law. 
 9.    Assignment. Neither you, the
Company nor Parent may make any assignment of this letter agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other parties; provided, however, that each of the Company and Parent may
assign its rights and obligations under this letter agreement without your consent to one of its Affiliates or to any Person with whom it shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or
substantially all of its properties or assets. This letter agreement shall inure to the benefit of and be binding upon you, the Company and Parent, and each of our respective successors, executors, administrators, heirs and permitted assigns. 

10.    Severability. If any portion or provision of this letter agreement shall to any extent be declared illegal
or unenforceable by a court of competent jurisdiction, then the remainder of this letter agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not
be affected thereby, and each portion and provision of this letter agreement shall be valid and enforceable to the fullest extent permitted by law. 

11.    Miscellaneous. This letter agreement sets forth the entire agreement between you and the Company and
replaces all prior and contemporaneous communications, agreements and understandings, written or oral, with respect to the terms and conditions of your employment with the Company. This letter agreement may not be modified or amended, and no breach
shall be deemed to be waived, unless agreed to in writing by you and the Company. The headings and captions in this letter agreement are for convenience only and in no way define or describe the scope or content of any provision of this letter
agreement. The words “include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation.” This letter
agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument. This is a California contract and shall be governed and construed in accordance with
the laws of the State of California, without regard to the conflict of laws principles thereof. Nothing in this letter agreement or any other Company agreement, policy, practice, procedure, directive or instruction limits your ability to
(a) file a charge or complaint with any governmental agency, governmental commission or other governmental authority (“Governmental Authority”), (b) report possible violations of law or regulation to any
Governmental Authority, (c) make other disclosures that are protected under the whistleblower provisions of applicable law or regulation, or (d) receive a whistleblower or other award from a

 John Walker 

August 9, 2017 
  Page
 9
 
  

 
Governmental Authority for information provided to a Governmental Authority. You do not need permission from anyone at the Company or the Company’s legal counsel in order to take any of the
actions described in the preceding sentence, and you do not have to notify the Company that you have taken or intend to take any of these actions. In addition, nothing in this Agreement is intended to interfere with or restrain the immunity provided
under 18 U.S.C. section 1833(b) for confidential disclosures of trade secrets (x) to lawyers or government officials solely for the purpose of reporting or investigating a suspected violation of law or (y) in a sealed filing in court or
another legal proceeding. 
 12.    Notices. Any notices provided for in this letter agreement shall be in
writing and shall be effective when delivered in person or deposited in the United States mail, postage prepaid, and addressed to you at your last known address on the books of the Company or, in the case of the Company, to it at its principal place
of business, or to such other address as either party may specify by notice to the other actually received. 

13.    No Non-Employee Director Compensation. You acknowledge and agree
that effective as of the Start Date you shall no longer be eligible to receive non-employee director compensation for your service as a member of the Board or as Chairman of the Board. 

14.    Cash Payment. You acknowledge and agree that pursuant to the terms of the Consulting Agreement, you shall be
entitled to receive $4,000 in cash compensation for Services (as defined in the Consulting Agreement) rendered in August 2017 prior to the Start Date and that you shall have no additional rights to compensation, benefits or otherwise under the
Consulting Agreement effective as of the Start Date. 
 15.    Restricted Stock Award. In consideration of your
appointment as President and Chief Executive Officer of the Parent and the Company effective as of the Start Date, the Company shall amend the vesting terms of the restricted stock award of 60,000 shares of Common Stock (the “RS
Award”) granted to you on May 18, 2017 pursuant to the terms of that certain Restricted Stock Agreement by and between you and the Parent (the “RS Agreement”), such that, in addition to the 30,000 shares of
Common Stock that are Vested Shares (as defined in the RS Agreement) as of the Start Date, an additional 3,334 shares of Common Stock shall be deemed Vested Shares as of the Start Date. You acknowledge and agree that the remaining 26,666 shares of
Common Stock underlying the RS Award shall be forfeited to the Parent on the Start Date without payment of any consideration by the Parent in connection with the termination of the Consulting Agreement. 

* * * * * 

 John Walker 

August 9, 2017 
  Page
 10
 
  

 At the time this letter agreement is signed by you and on behalf of the Company and Parent,
it will take effect as a binding agreement among you, the Company and Parent on the basis set forth above. 
  

									
	ZOSANO PHARMA CORPORATION	 		 	EMPLOYEE:
				
	By:	 	 /s/ Georgia Erbez
	 		 	 /s/ John Walker

		 	Name:	 	Georgia Erbez	 		 	John Walker
		 	Title:	 	Chief Business Officer and Chief Financial Officer	 		 	
					
		 		 		 		 	Date signed: August 17, 2017
			
	ZP OPCO, INC.	 		 	
				
	By:	 	 /s/ Georgia Erbez
	 		 	
		 	Name:	 	Georgia Erbez	 		 	
		 	Title:	 	Chief Business Officer and Chief Financial Officerex10-1.htm

Exhibit 10.1

 

AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT

 

THIS AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT (this “Amendment”), dated as of July 21, 2017, amends that certain Supply Agreement (the “Supply Agreement”), effective the 14th day of March, 2016, between Greatbatch Ltd., having an office at 10000 Wehrle Drive, Clarence, New York 14031 (“Greatbatch”) and Nuvectra Corporation (f/k/a QIG Group, LLC), having an office at 5700 Granite Parkway, Suite 960, Plano, Texas, 75024 (“Nuvectra”).

 

WHEREAS, Greatbatch and Nuvectra wish to amend the Supply Agreement in order to, amongst other things, amend the pricing for certain Products in Appendix B.

 

NOW, THEREFORE, for good and lawful consideration, the sufficiency of which is hereby acknowledged and agreed, the parties hereto (individually, a “Party”; collectively, the “Parties”) hereby agree as follows:

 

1.     Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings assigned to them in the Supply Agreement.

 

 

 

2.     Amendment to Agreement. The Supply Agreement is hereby amended by replacing all references to “QiG Group, LLC” with “Nuvectra Corporation” and “QiG Group” with “Nuvectra”. 

 

 

 

3.     Amendment to Article II. Article II of the Supply Agreement is hereby amended by adding the following new Section II.D:

 

 

 

“D.     Annual Minimums. Notwithstanding anything in this Agreement to the contrary, during each calendar year during the Term, Nuvectra shall purchase at least [***] implantable pulse generator Products and at least [***] lead/extension Products, which shall be determined by the aggregate purchases of any and all make/model numbers for implantable pulse generator Products and lead/extension Products, as applicable.”

 

 

 

4.     Amendment to Appendix B. Appendix B of the Supply Agreement is hereby amended by replacing it in its entirety with Annex I attached hereto.

 

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

 

 

    

5.     Miscellaneous.

 

 

(a)     Except as provided herein, all terms and conditions of the Supply Agreement shall remain in full force and effect.

 

(b)     This Amendment may be executed in counterparts, all of which together shall constitute one agreement binding on all of the Parties, notwithstanding that all of the Parties are not signatories to the original or the same counterpart.

 

 

(c)     This Amendment expresses the entire understanding of the Parties with respect to the matters set forth herein and supersedes all prior discussions or negotiations hereon.

 

 

(d)     This Amendment, and all claims arising in whole or in part out of, related to, based upon, or in connection herewith or the subject matter hereof will be governed by and construed and enforced in accordance with the substantive laws of the State of New York, without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.

 

 

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first set forth above.

 

 

GREATBATCH LTD.

 

 

By: __/s/ Antonio Gonzalez________

Name: Antonio Gonzalez

Title: President, CRMN

 

 

 

NUVECTRA CORPORATION

 

 

By: __/s/ Scott F. Drees____________

Name: Scott F. Drees

Title: CEO

 

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

 

 

 

Annex I

 

APPENDIX B

TO SUPPLY AGREEMENT

 

Prices

 

IPG Pricing

	
IPG Pricing for IPGs delivered prior to July 1, 2018

	
IPG
	
2016
	
2017
	
2018

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	  	  	  	  
	  	  	  	  
	
IPG Pricing for IPGs delivered on or after July 1, 2018

	
IPG
	
2018
	
2019
	
2020

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

 

The parties hereby acknowledge and agree that they will be negotiating in good faith an amendment to this Agreement to add the Pelvistim product line to this Agreement (the “Pelvistim Amendment”). The parties hereby agree that so long as the specifications of the Pelvistim IPG are materially and substantially similar to the Specifications of the Algovita IPG (with the exception of the firmware), the price for the Pelvistim IPG will be [***] the Algovita IPG pricing set forth above; provided, that in the event that the specifications of the Pelvistim IPG are not materially and substantially similar to the Specifications of the Algovita IPG (with the exception of the firmware), the parties will negotiate in good faith an adjustment to the price of the Pelvistim IPG. For purposes of calculating the annual volumes above, the total quantities of the Algovita IPGs and the Pelvistim IPGs purchased and delivered in the relevant calendar year shall be combined.

 

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

  

 

 

 

 

Leads/Extensions Pricing

 

	
Leads/Extensions Pricing for Leads/Extensions delivered prior to July 1, 2018

	
Leads
	
2016
	
2017
	
2018

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	  	  	  	  
	  	  	  	  
	
Leads/Extensions Pricing for Leads/Extensions delivered on or after July 1, 2018

	
Leads
	
2018
	
2019
	
2020

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

	
[***]
	
$[***]
	
$[***]
	
$[***]

 

The parties hereby agree that the price for the Pelvistim Leads/Extensions with the specifications set forth in that certain [***] (the “Pelvistim Lead/Extension Specifications”) will [***] the Algovita Leads/Extensions pricing set forth above; provided, that in the event that the Pelvistim Lead/Extension Specifications materially change prior to the execution of the Pelvistim Amendment, the parties will negotiate in good faith an adjustment to the price of the Pelvistim Leads/Extensions. For purposes of calculating the annual volumes above, the total quantities of the Algovita Leads/Extensions and the Pelvistim Leads/Extensions purchased and delivered in the relevant calendar year shall be combined.

 

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

 

 

  

Purchased Components Pricing

 

 

 

	
ALL VOLUMES/ALL YEARS

	
Cable    
	
$[***]

	
Tunneling Tool    
	
$[***]

	
 
	
 

	
Accessories
	
Price

	
Anchor (Box [***]) 5400
	
$[***]

	
Trque Wrnch (Box [***]) 5500
	
$[***]

	
Port Plug (Box [***]) 5510
	
$[***]

	
Needle (St) [***] ea 5300
	
$[***]

	
Needle (Lng) [***] ea 5310
	
$[***]

	
Passing Elevator 5600
	
$[***]

	
Adhesive Anchor 5410
	
$[***]

	
Magnet 4900
	
$[***]

	
Adhesive Patches 4240
	
$[***]

	
Adjustable Belt 4220
	
$[***]

	
Prog. Power Cord 4010
	
$[***]

	
Trial Stim Pouch 4320
	
$[***]

 

 

 

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED WITH [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]